Cargando…
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
PURPOSE: To compare using immuno-PET/CT the distribution of (89)Zr-labelled rituximab without and with a preload of unlabelled rituximab to assess the impact of preloading with unlabelled rituximab on tumour targeting and radiation dose of subsequent radioimmunotherapy with (90)Y-labelled rituximab...
Autores principales: | Muylle, Kristoff, Flamen, Patrick, Vugts, Danielle J., Guiot, Thomas, Ghanem, Ghanem, Meuleman, Nathalie, Bourgeois, Pierre, Vanderlinden, Bruno, van Dongen, Guus A. M. S., Everaert, Hendrik, Vaes, Mélanie, Bron, Dominique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480335/ https://www.ncbi.nlm.nih.gov/pubmed/25792453 http://dx.doi.org/10.1007/s00259-015-3025-6 |
Ejemplares similares
-
Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
por: Hagens, Marloes HJ, et al.
Publicado: (2017) -
B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients
por: Bruijnen, Stefan, et al.
Publicado: (2016) -
Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011) -
[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial
por: Adams, H., et al.
Publicado: (2023) -
Rituximab
por: Tridente, Giuseppe
Publicado: (2013)